Attacks marked by spinal cord inflammation significantly increase the chance of worse disability in NMOSD and MOGAD, per a study.| Neuromyelitis News
Understanding the body’s limits is key to conserving energy, writes columnist Jennifer V., who prioritizes her daily tasks with rest in mind.| Neuromyelitis News
Living with NMOSD and its resulting disability can make it hard to find and keep employment, a new U.S. study highlights.| Neuromyelitis News
Nearly all neuromyelitis optica spectrum disorder patients who took Enspryng are free from relapses after six months, a Japanese study shows.| Neuromyelitis News
Category archive page for News.| Neuromyelitis News
Steve Bryson is a science writer for Neuromyelitis News with a PhD in biochemistry. He covers the latest news and information on a variety of NMO topics.| Neuromyelitis News
Off-label rituximab significantly reduces the risk of relapse and lessens disability in most NMOSD patients, a long-term study showed.| Neuromyelitis News
Uplizna safely provided sustained disease control for NMOSD patients, according to final data from a Phase 2/3 clinical trial.| Neuromyelitis News